Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Xiaosen Ma"'
Autor:
Yue Zhou, Yinjie Gao, Xiaosen Ma, Tianyi Li, Yunying Cui, Yu Wang, Ming Li, Dingding Zhang, Anli Tong
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
AimTo develop and internally validate a novel predictive model for SDHB mutations in pheochromocytomas and retroperitoneal paragangliomas (PPGLs).MethodsClinical data of patients with PPGLs who presented to Peking Union Medical College Hospital from
Externí odkaz:
https://doaj.org/article/ae6df6ea808d4eb1b673a7bf8d424de6
Autor:
Xiaosen Ma, Chao Ling, Meng Zhao, Fen Wang, Yunying Cui, Jin Wen, Zhigang Ji, Caili Zhang, Shi Chen, Anli Tong, Yuxiu Li
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
PurposePheochromocytoma/paraganglioma (PCC/PGL; collectively known as PPGL) can be driven by germline and somatic mutations in susceptibility genes. We aimed to investigate the mutation profile and clinical features of pathogenic genes in highly gene
Externí odkaz:
https://doaj.org/article/ec360579d4af44daab83136fbecd218c
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
ObjectiveTo study the characteristics, risk factors, and outcomes of local-regional recurrence of pheochromocytoma and paraganglioma (PPGL).MethodsClinical data of 96 PPGL patients with local-regional recurrence and 112 patients without recurrence we
Externí odkaz:
https://doaj.org/article/49627f37d5c24641aeaf8cb68a43c342
Autor:
Huiping Wang, Fen Wang, Yushi Zhang, Jin Wen, Dexin Dong, Xiaoyan Chang, Hao Sun, Xiaosen Ma, Yunying Cui, Shi Chen, Lin Lu, Weidong Ren, Anli Tong, Yuxiu Li
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
IntroductionPrevious studies on the surgical outcomes of aldosterone-producing adenoma (APA) patients were mainly based on the histopathological diagnosis of HE staining or adrenal venous sampling (AVS) instead of the functional pathology. The aim of
Externí odkaz:
https://doaj.org/article/590ff52336034a4abc3ce86a2ddfd62c
Publikováno v:
International Journal of Endocrinology, Vol 2021 (2021)
Purpose. Recently, pheochromocytomas and paragangliomas (PPGLs) have been strongly suspected as hereditary tumors, as approximately 40% of patients carry germline mutations. In the cancers where defects occur to corrupt DNA repair and facilitate tumo
Externí odkaz:
https://doaj.org/article/b390ea4c3a744971b2724af03afc0a5f
Publikováno v:
International Journal of Endocrinology, Vol 2021 (2021)
Purpose. Previous studies have investigated the transcriptional modulations of aldosterone overproduction of aldosterone-producing adenomas (APAs). We aimed to systematically study the genes and pathways associated with molecular mechanism underlying
Externí odkaz:
https://doaj.org/article/a4c6ec41c2fe45fcbf8b83e52425af7b
Autor:
Xiaosen Ma, Ming Li, Anli Tong, Fen Wang, Yunying Cui, Xuebin Zhang, Yushi Zhang, Shi Chen, Yuxiu Li
Publikováno v:
Frontiers in Endocrinology, Vol 11 (2020)
Pheochromocytoma/paraganglioma (PPGL) has a high genetic heterogeneity with 40% germline variants in known pathogenic genes. Data in Chinese on this aspect are scanty. To detect the genetic and clinical profile of Chinese PPGL patients, we examined t
Externí odkaz:
https://doaj.org/article/2bbe293f910f47bca61beddce800e15b
Publikováno v:
Frontiers in Endocrinology, Vol 11 (2020)
Background:MYC associated factor X (MAX) is a tumor suppressor gene and has been identified as one of the pathogenic genes of hereditary pheochromocytoma (PCC). To date, there have been no reports of ganglioneuroma (GN) with MAX variants.Case Present
Externí odkaz:
https://doaj.org/article/65ee193656dc4a2cb226ed050f3c9cd5
Publikováno v:
Frontiers in Endocrinology, Vol 11 (2020)
Purpose: The aim of this study is to examine the effects of different kinds of calcium channel blockers (CCBs) on primary aldosterone-producing adenoma (APA) mainly with KCNJ5 mutations. Primary cultured APA cells were treated with different calcium
Externí odkaz:
https://doaj.org/article/5fad4a0a3c7f414cbd103ffb2fd3b565
Publikováno v:
Frontiers in Endocrinology, Vol 11 (2020)
Context: Metastatic pheochromocytoma/paraganglioma (MPP) therapy mainly involves radionuclide therapy, chemotherapy, and targeted therapy. In recent years, temozolomide (TMZ) showed great promise in some MMP patients, especially those with SDHB germl
Externí odkaz:
https://doaj.org/article/c0f6583c6d4448babdecc2e200cc1f57